Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease.

BÜHLMANN fCAL® ELISA Citation

Pavlidis, P. et al., 2016, Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease, Scandinavian Journal of Gastroenterology.  PMID: 27400728  DOI: 10.1080/00365521.2016.1205128

Highlight from this Publication

“The ΔFCAL could act as an ‘early warning’ to consider alternatives such as dose optimisation or another biologic with a different mode of action, rather than persisting for several months.”

Read Citation

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic Use.

Health Canada License: 80726

This citation describes applications that are outside of product claims (Intended use is: The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.)